Europe Gastrointestinal Drugs Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
The Europe Gastrointestinal Drugs Market size was valued at US$ 19,650.29 Mn in 2023 and is projected to reach US$ 34,299.35 Mn by 2031, growing at a CAGR of 7.2% during 2023 - 2031.
Report Coverage
- Drug Class: Biologics, Antidiarrheal and Laxatives, Acid Neutralizers, Anti-inflammatory Drugs, Antiemetic and Antinauseants, Others
- Application: Irritable Bowel Syndrome, Inflammatory Ulcerative Colitis, Crohn\'s Disease, Gastroenteritis, Celiac Disease, Others
- Route Of Administration: Oral, Parenteral
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
US$ 19,650.29 Mn
Market size in 2023
US$ 34,299.35 Mn
Market Size by 2031
7.2%
CAGR, 2023 - 2031
2024-2031
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Gastrointestinal Drugs Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Gastrointestinal Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Gastrointestinal Drugs Market Regional Analysis
6.2 Europe Gastrointestinal Drugs Market Revenue 2021-2031 (US$ Million)
6.3 Europe Gastrointestinal Drugs Market Forecast Analysis
7. Europe Gastrointestinal Drugs Market Analysis – by Drug Class
7.1 Biologics
- 7.1.1 Overview
- 7.1.2 Biologics: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Antidiarrheal and Laxatives
- 7.2.1 Overview
- 7.2.2 Antidiarrheal and Laxatives: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Acid Neutralizers
- 7.3.1 Overview
- 7.3.2 Acid Neutralizers: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Anti-inflammatory Drugs
- 7.4.1 Overview
- 7.4.2 Anti-inflammatory Drugs: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Antiemetic and Antinauseants
- 7.5.1 Overview
- 7.5.2 Antiemetic and Antinauseants: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Europe Gastrointestinal Drugs Market Analysis – by Application
8.1 Irritable Bowel Syndrome
- 8.1.1 Overview
- 8.1.2 Irritable Bowel Syndrome: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Inflammatory Ulcerative Colitis
- 8.2.1 Overview
- 8.2.2 Inflammatory Ulcerative Colitis: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Crohn\'s Disease
- 8.3.1 Overview
- 8.3.2 Crohn\'s Disease: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Gastroenteritis
- 8.4.1 Overview
- 8.4.2 Gastroenteritis: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Celiac Disease
- 8.5.1 Overview
- 8.5.2 Celiac Disease: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Europe Gastrointestinal Drugs Market Analysis – by Route Of Administration
9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Parenteral
- 9.2.1 Overview
- 9.2.2 Parenteral: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Europe Gastrointestinal Drugs Market Analysis – by Distribution Channel
10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: Europe Gastrointestinal Drugs Market – Revenue and Forecast, 2021-2031 (US$ Million)
11. Europe Gastrointestinal Drugs Market – Europe Analysis
11.1 Overview
11.2 Europe- 11.2.1 Europe Gastrointestinal Drugs Market Breakdown, by Key Country, 2024 and 2031 (%)
- 11.2.1.1 Europe Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Country
- 11.2.1.1 UK: Europe Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.1.1 UK: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.1.2 UK: Europe Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.1.3 UK: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.1.4 UK: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
- 11.2.1.2 Germany: Europe Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.2.1 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.2.2 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.2.3 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.2.4 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
- 11.2.1.3 France: Europe Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.3.1 France: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.3.2 France: Europe Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.3.3 France: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.3.4 France: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
- 11.2.1.4 Italy: Europe Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.4.1 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.4.2 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.4.3 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.4.4 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
- 11.2.1.5 Spain: Europe Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.5.1 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.5.2 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.5.3 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.5.4 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
- 11.2.1.6 Rest of Europe: Europe Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.6.1 Rest of Europe: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
- 11.2.1.6.2 Rest of Europe: Europe Gastrointestinal Drugs Market Breakdown, by Application
- 11.2.1.6.3 Rest of Europe: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
- 11.2.1.6.4 Rest of Europe: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Sanofi SA
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 GSK Plc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Johnson & Johnson
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Bausch Health Companies Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 AstraZeneca Plc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 AbbVie Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Bayer AG
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Celltrion Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Pfizer Inc
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Access the Full E Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
